EHC at a glance
Encompass Health Corp (EHC, SEC CIK 785161) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as September 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Encompass Health Corp (EHC) reported revenue of $5.9 billion (up 10.5% from FY2024) and net income of $566.2 million. Diluted EPS was $5.54.
- As of June 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Encompass Health Corp (EHC) shares worth $4.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Darby John Patrick on August 31, 2026 of 4,858 shares at $121.09 per share.
- In the last 90 days, EHC insiders reported 0 open-market purchases ($0) and 6 open-market sales ($26.4M) on Form 4, a net sale of $26.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.9B
- +10.5% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$26.4M
- 13F holders
- 39 funds
- $4.8B · +0 vs prior quarter
- Latest 10-Q
- Aug 7, 2026
- Quarterly report
SignalX for EHC
Don't miss the next EHC filing
- Alerts as it files. A push when EHC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EHC, by share count.
- Ask anything. An AI agent that reads every EHC filing and answers with sources.
EHC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Darby John Patrick | M | Aug 31, 2026 | 4,858 | $35.06 |
| Darby John Patrick | Sell | Aug 31, 2026 | 4,858 | $121.09 |
| Darby John Patrick | M | Aug 31, 2026 | 4,858 | - |
| Price Andrew L | Sell | Aug 31, 2026 | 5,211 | $120.93 |
| Tarr Mark J | Sell | Aug 10, 2026 | 1,579 | $126.06 |
| Darby John Patrick | Sell | Aug 10, 2026 | 8,906 | $125.95 |
| COLTHARP DOUGLAS E | Sell | Aug 10, 2026 | 18,869 | $125.38 |
| Tarr Mark J | Sell | Aug 10, 2026 | 171,569 | $125.46 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $4.8B | $5.4B | $5.9B | |
| Net Income | $352.0M | $455.7M | $566.2M | |
| Net Margin | 7.3% | 8.5% | 9.5% | |
| Balance Sheet | ||||
| Total Assets | $6.1B | $6.5B | $7.1B | |
| Equity | $1.6B | $2.1B | $2.4B | |
| ROE | 21.4% | 22.0% | 23.2% | |
| Per Share | ||||
| EPS | $3.47 | $4.46 | $5.54 | |
| Cash Flow | ||||
| Operating CF | $850.8M | $1.0B | $1.2B | |
Source: XBRL data in Encompass Health Corp (EHC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate EHC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 39 | $4.81B |
| Q1 2026 | 39 | $4.62B |
| Q4 2025 | 36 | $4.97B |
| Q3 2025 | 37 | $6.18B |
| Q2 2025 | 37 | $5.55B |
| Q1 2025 | 35 | $3.53B |
| Q4 2024 | 28 | $2.75B |
| Q3 2024 | 24 | $1.60B |
- Citadel Advisors LLC+2.05M (+401%)
- T. Rowe Price Group+455.3K (+10%)
- Millennium Management+327.9K (+69%)
- Morgan Stanley+249.9K (+28%)
- Dimensional Fund Advisors+68.2K (+4%)
- Invesco Ltd−2.22M (-66%)
- BlackRock−284.3K (-3%)
- Goldman Sachs Group−254.9K (-14%)
- Franklin Resources−245.3K (-29%)
- D.E. Shaw & Co−180.8K (-32%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 275 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EHC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- MD · Pediatrix Medical Group, Inc.Services-Hospitals
- SEM · SELECT MEDICAL HOLDINGS CORPServices-Hospitals
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
EHC SEC filings: frequently asked questions
Are EHC insiders buying or selling?
In the last 90 days, Encompass Health Corp (EHC) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $26.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EHC stock?
As of June 30, 2026, the largest Encompass Health Corp (EHC) holders among the 13F filers tracked by SignalX were BlackRock ($1.1 billion), T. Rowe Price Group ($511.0 million), Vanguard Portfolio Management LLC ($497.8 million), Vanguard Capital Management LLC ($452.4 million), State Street Corp ($322.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EHC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Encompass Health Corp (EHC) reported revenue of $5.9 billion (up 10.5% from FY2024) and net income of $566.2 million. Diluted EPS was $5.54. The figures come from the XBRL data in the 10-K.
What are the latest EHC SEC filings?
Encompass Health Corp (EHC) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on September 1, 2026.
What is EHC's SEC CIK number?
Encompass Health Corp (EHC)'s SEC Central Index Key (CIK) is 785161. EDGAR lists every EHC filing under that number.
Ask anything about EHC
The research agent reads EHC's filings, financials, insider trades and 13F holders, then answers with sources.